Ullrich Graeven

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

Claus Rödel, Ullrich Graeven, Rainer Fietkau et al. · The Lancet Oncology · 2015 · 713 citations

Final Results, Radiation Medicine, Radiation Therapy +9

Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial

Claus Rödel, Torsten Liersch, Heinz Becker et al. · The Lancet Oncology · 2012 · 694 citations

Surgical Oncology, Radiation Therapy, Gastrointestinal Oncology +8

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

Jim Cassidy, Chris Twelves, Eric Van Cutsem et al. · Annals of Oncology · 2002 · 521 citations

Oncology, Gastrointestinal Oncology, Cancer Management +6

Vascular Endothelial Growth Factor, a Possible Paracrine Growth Factor in Human Acute Myeloid Leukemia

Walter Fiedler, Ullrich Graeven, Süleyman Ergün et al. · Blood · 1997 · 446 citations · Full text

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

Eric Van Cutsem, Paulo M. Hoff, Peter Harper et al. · British Journal of Cancer · 2004 · 396 citations · Full text